Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1650

Sort by

Sort Order Select

Journal Articles

CBL mutations drive PI3K/AKT signaling via increased interaction with LYN and PIK3R1

Roger Belizaire, Sebastian H. J. Koochaki, Namrata D. Udeshi, Alexis Vedder, Lei Sun, Tanya Svinkina, Christina Hartigan, Marie McConkey, Veronica Kovalcik, Amanuel Bizuayehu, Caroline Stanclift, Monica Schenone, Steven A. Carr, Eric Padron, Benjamin L. Ebert

Blood (2021) 137 (16): 2209–2220.

https://doi.org/10.1182/blood.2020006528

Published: 2021

Includes: Supplemental data

Journal Articles

Interplay between the tyrosine kinases Chk and Csk and phosphatase PTPRJ is critical for regulating platelets in mice

Zoltan Nagy, Jun Mori, Vanesa-Sindi Ivanova, Alexandra Mazharian, Yotis A. Senis

Blood (2020) 135 (18): 1574–1587.

https://doi.org/10.1182/blood.2019002848

Published: 2020

Includes: Supplemental data

Journal Articles

Stat3 Is Activated By ROS to Uniquely Regulate Primitive Erythropoiesis

Zachary C. Murphy, PhD, Kathleen E. McGrath, PhD, James Palis, MD

Blood (2019) 134 (Supplement_1): 2216.

https://doi.org/10.1182/blood-2019-127229

Published: 2019

Journal Articles

Antibody Cloning Identifies Pathogenic and Non-Pathogenic Antibodies in Heparin-Induced Thrombocytopenia and Defines the Molecular Signatures That Differentiate the Two Types of Antibodies

Wen Zhu, Yongwei Zheng, PhD, Mei Yu, PhD, Yaling Wu, Jianhui Wei, Nicholas Schneider, Anand Padmanabhan, MD PhD, Richard H. Aster, MD, Demin Wang, PhD, Renren Wen, PhD

Blood (2019) 134 (Supplement_1): 439.

https://doi.org/10.1182/blood-2019-126097

Published: 2019

Journal Articles

CLL B Cells Develop Resistance to Ibrutinib By Reinvigorating the IL-4R - IL-4 Axis Blocked By Bruton's Tyrosine Kinase Inhibitors Including Acalabrutinib and Zanubrutinib

Shih-Shih Chen, PhD, Constantine S. Tam, MBBS (Hons), MD, Alan G. Ramsay, BSc,MSc,PhD, Priyadarshini Ravichandran, Natalia C. Couto-Francisco, Michael Ibrahim, Gerardo Ferrer, PhD, Jonathan E. Kolitz, MD, Steven L. Allen, MD, He Zhou, Jacqueline C Barrientos, MD, Kanti R Rai, MD, Nicholas Chiorazzi, MD

Blood (2019) 134 (Supplement_1): 477.

https://doi.org/10.1182/blood-2019-127255

Published: 2019

Journal Articles

Deletion of CISH in Human Pluripotent Stem Cell-Derived Natural Killer Cells Enhances Anti-Tumor Activity Via Metabolic Reprogramming

Huang Zhu, PhD, Robert Blum, Zhengming Wu, Zhipeng Meng, PhD, Kun-Liang Guan, PhD, Dan S Kaufman, MD PhD

Blood (2019) 134 (Supplement_1): 619.

https://doi.org/10.1182/blood-2019-124446

Published: 2019

Journal Articles

Discovery & Characterization of Therapeutically Targetable Ntrk Point Mutations in Leukemia

Sunil K Joshi, BA, William Bisson, PhD, Kristin Qian, Ariane Huang, Kevin Watanabe-Smith, PhD, Jeffrey W. Tyner, Monika Ashok Davare, PhD, Shannon K. McWeeney, PhD, Cristina E. Tognon, Brian J. Druker

Blood (2019) 134 (Supplement_1): 1256.

https://doi.org/10.1182/blood-2019-125908

Published: 2019

Journal Articles

Fibrinogen Activates FAK to Promote the Colorectal Adenocarcinoma Growth

Balkrishan Sharma, PhD, Duaa Mureb, BS, Sumit Murab, PhD, Leah A. Rosenfeldt, BS, Brenton J Francisco, MD, Alexander A Boucher, MD, Rachel Cantrell, BS, Jacob Mast, Matthew J. Flick, PhD, Patrick W Whitlock, MD, Joseph S. Palumbo, MD

Blood (2019) 134 (Supplement_1): 1111.

https://doi.org/10.1182/blood-2019-130497

Published: 2019

Journal Articles

Cage Transcriptome Analysis Reveals BCL2A1 Upregulation in FLT3 -ITD/D835 Dual Mutated AML Cells Harboring Complex Co-Mutations

Kotoko Yamatani, MD, Tomohiko Ai, MD PhD, Kaori Saito, Haeun Yang, Koya Suzuki, PhD, Atsushi Hori, PhD, Yuko Murakami-Tonami, MD PhD, Weiguo Zhang, MD PhD, Bing Z Carter, PhD, Sonoko Kinjo, PhD, Kazuho Ikeo, PhD, Katayama Kazuhiro, Hironori Harada, MD PhD, Takashi Miida, MD PhD, Neil P. Shah, MD PhD, Marina Y Konopleva, MD PhD, Yoshihide Hayashizaki, MD PhD, Michael Andreeff, MD PhD, Yoko Tabe, MD PhD

Blood (2019) 134 (Supplement_1): 1264.

https://doi.org/10.1182/blood-2019-124685

Published: 2019

Journal Articles

PP2A Activators Enhance Efficacy of FLT3 Inhibitors in FLT3-ITD Acute Myeloid Leukemia Cells through AKT Inactivation-Dependent Pim-1 and c-Myc Proteasomal Degradation

Mario Scarpa, PhD, Prerna Singh, MS, Shivani Kapoor, MS, Jonelle K. Lee, MS, Sandrine Niyongere, MD, Goutham Narla, MD PhD, Danilo Perrotti, MD PhD, Maria R. Baer, MD

Blood (2019) 134 (Supplement_1): 1276.

https://doi.org/10.1182/blood-2019-129011

Published: 2019

Journal Articles

KLHL14 Is a Tumor Suppressor in Diffuse Large B-Cell Lymphoma

Jaewoo Choi, PhD, James D Phelan, PhD, Ryan M. Young, PhD, Thomas Oellerich, MD, Da Wei Huang, MD, Arthur L Shaffer, PhD, Louis Staudt, MD

Blood (2019) 134 (Supplement_1): 2766.

https://doi.org/10.1182/blood-2019-125137

Published: 2019

Journal Articles

DOCK2 Expression Affects Leukemogenesis and Disease Progression in a Murine Model of FLT3/ITD Acute Myeloid Leukemia

Min Wu, PhD, Li Li, MD PhD, Donald Small, MD PhD, Amy S. Duffield, MD PhD

Blood (2019) 134 (Supplement_1): 2534.

https://doi.org/10.1182/blood-2019-129157

Published: 2019

Journal Articles

Gilteritinib and Venetoclax Synergize to Eliminate FLT3/ITD+ Leukemia Cells through BIM

Ruiqi Zhu, PhD, Li Li, MD PhD, Bao Nguyen, MS, Amy S. Duffield, MD PhD, Donald Small, MD PhD

Blood (2019) 134 (Supplement_1): 2564.

https://doi.org/10.1182/blood-2019-131635

Published: 2019

Journal Articles

DYRK1A Is Regulated By Oncogenic KMT2A and Required for Survival of KMT2A -Rearranged Acute Lymphoblastic Leukemia

Christian Hurtz, PhD, Gerald Wertheim, MD, PhD, Rahul S. Bhansali, Anne Lehman, Grace Jeschke, PhD, John D. Crispino, PhD MBA, Thierry Besson, PhD, Sarah K. Tasian, MD, Martin Carroll, MD

Blood (2019) 134 (Supplement_1): 2742.

https://doi.org/10.1182/blood-2019-123475

Published: 2019

Journal Articles

The Role of Protein Tyrosine Phosphatase PTP4A3 in T-Cell Acute Lymphoblastic Leukemia Progression

Min Wei, MSc, Jessica Blackburn, PhD

Blood (2019) 134 (Supplement_1): 2539.

https://doi.org/10.1182/blood-2019-126256

Published: 2019

Journal Articles

BCR-ABL and Src Family Kinases Induce YAP Tyrosine Phosphorylation Resulting in Survivin and Cyclin D1 Expression in Chronic Myeloid Leukemia Cells

Toshiyuki Hori, MD PhD, Kenta Moriyama, MS

Blood (2019) 134 (Supplement_1): 5366.

https://doi.org/10.1182/blood-2019-124643

Published: 2019

Journal Articles

A Phase 1b Study Evaluating the Safety and Efficacy of Topical Administration of WP1220, an Inhibitor of STAT3 Activation, in Stage I, II or III Mycosis Fungoides (MF)

Malgorzata Sokołowska-Wojdyło, MD, Izabela Blazewicz, PhD, Berenika Olszweska, PhD, Ewa Maria Zak, MSc, Walter Klemp, Sandra L Silberman, MD PhD, Waldemar Priebe, PhD

Blood (2019) 134 (Supplement_1): 5272.

https://doi.org/10.1182/blood-2019-125118

Published: 2019

Journal Articles

ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Mantle Cell Lymphoma (MCL) Cells

Håkan Mellstedt, MD PhD Prof., Amineh Ghaderi, MSc, Johanna Aschan, MSc, Fariba Mozaffari, MSc,PhD, Ali Moshfegh, MSc,PhD, Birgitta Sander, MD PhD Prof., Johan Schultz, MSc,PhD, Martin Norin, MSc,PhD, Thomas Olin, MSc,PhD, Elias Drakos, MD PhD Prof., George Z. Rassidakis, MD PhD Prof., Anders Österborg, MD PhD, Mohammad Hojjat-Farsangi, MSc,PhD

Blood (2019) 134 (Supplement_1): 5312.

https://doi.org/10.1182/blood-2019-129773

Published: 2019

Journal Articles

RMC-4550, an Allosteric Inhibitor of SHP2, Displays Therapeutic Efficacy in Pre-Clinical Models of Myeloproliferative Neoplasms

Garima Pandey, Nathan Horvat, Narmin E. Amin, Afua A. Akuffo, Christelle Colin, Pearlie K. Epling-Burnette, Gary W. Reuther

Blood (2019) 134 (Supplement_1): 4198.

https://doi.org/10.1182/blood-2019-128937

Published: 2019

Journal Articles

Bosutinib in the Real-Life Treatment of Chronic Phase Chronic Myeloid Leukemia (CML) Patients Aged > 65 Years Resistant/Intolerant to Frontline Tyrosine-Kynase Inhibitors

Blood (2019) 134 (Supplement_1): 1649.

https://doi.org/10.1182/blood-2019-127029

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

CBL mutations drive PI3K/AKT signaling via increased interaction with LYN and PIK3R1

Interplay between the tyrosine kinases Chk and Csk and phosphatase PTPRJ is critical for regulating platelets in mice

Stat3 Is Activated By ROS to Uniquely Regulate Primitive Erythropoiesis

Antibody Cloning Identifies Pathogenic and Non-Pathogenic Antibodies in Heparin-Induced Thrombocytopenia and Defines the Molecular Signatures That Differentiate the Two Types of Antibodies

CLL B Cells Develop Resistance to Ibrutinib By Reinvigorating the IL-4R - IL-4 Axis Blocked By Bruton's Tyrosine Kinase Inhibitors Including Acalabrutinib and Zanubrutinib

Deletion of CISH in Human Pluripotent Stem Cell-Derived Natural Killer Cells Enhances Anti-Tumor Activity Via Metabolic Reprogramming

Discovery & Characterization of Therapeutically Targetable Ntrk Point Mutations in Leukemia

Fibrinogen Activates FAK to Promote the Colorectal Adenocarcinoma Growth

Cage Transcriptome Analysis Reveals BCL2A1 Upregulation in FLT3 -ITD/D835 Dual Mutated AML Cells Harboring Complex Co-Mutations

PP2A Activators Enhance Efficacy of FLT3 Inhibitors in FLT3-ITD Acute Myeloid Leukemia Cells through AKT Inactivation-Dependent Pim-1 and c-Myc Proteasomal Degradation

KLHL14 Is a Tumor Suppressor in Diffuse Large B-Cell Lymphoma

DOCK2 Expression Affects Leukemogenesis and Disease Progression in a Murine Model of FLT3/ITD Acute Myeloid Leukemia

Gilteritinib and Venetoclax Synergize to Eliminate FLT3/ITD+ Leukemia Cells through BIM

DYRK1A Is Regulated By Oncogenic KMT2A and Required for Survival of KMT2A -Rearranged Acute Lymphoblastic Leukemia

The Role of Protein Tyrosine Phosphatase PTP4A3 in T-Cell Acute Lymphoblastic Leukemia Progression

BCR-ABL and Src Family Kinases Induce YAP Tyrosine Phosphorylation Resulting in Survivin and Cyclin D1 Expression in Chronic Myeloid Leukemia Cells

A Phase 1b Study Evaluating the Safety and Efficacy of Topical Administration of WP1220, an Inhibitor of STAT3 Activation, in Stage I, II or III Mycosis Fungoides (MF)

ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Mantle Cell Lymphoma (MCL) Cells

RMC-4550, an Allosteric Inhibitor of SHP2, Displays Therapeutic Efficacy in Pre-Clinical Models of Myeloproliferative Neoplasms

Bosutinib in the Real-Life Treatment of Chronic Phase Chronic Myeloid Leukemia (CML) Patients Aged > 65 Years Resistant/Intolerant to Frontline Tyrosine-Kynase Inhibitors

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only